NASDAQ : GLUE
Monte Rosa Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 10.87 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 927.36M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 906.88M |
| Enterprise Value | 323.76M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 85.31M |
| Shares Outstanding | 85.31M |
| Shares Change (YoY) | +11.91% |
| Shares Change (QoQ) | +1.60% |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 80.75% |
| Float | 54.48M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 31.57 |
| Forward PS | 13.96 |
| PB Ratio | 1.88 |
| P/TBV Ratio | 1.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 11.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.58 |
| Quick Ratio | 10.49 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -42.66% |
| Return on Assets (ROA) | -21.63% |
| Return on Invested Capital (ROIC) | -27.24% |
| Return on Capital Employed (ROCE) | -28.80% |
| Weighted Average Cost of Capital (WACC) | 11.31% |
| Revenue Per Employee | $166,052 |
| Profits Per Employee | -$931,306 |
| Employee Count | 173 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -2.86M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.37 |
| 52-Week Price Change | -17.28% |
| 50-Day Moving Average | 12.00 |
| 200-Day Moving Average | 17.31 |
| Relative Strength Index (RSI) | 43.15 |
| Average Volume (20 Days) | 1,512,909 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 20.66M |
| Short Previous Month | 19.69M |
| Short % of Shares Out | 24.22% |
| Short % of Float | 37.93% |
| Short Ratio (days to cover) | 14.00 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 28.73M |
| Gross Profit | -133.63M |
| Operating Income | -181.85M |
| Pretax Income | -163.97M |
| Net Income | -161.12M |
| EBITDA | -173.73M |
| EBIT | -181.85M |
| Loss Per Share | -$1.75 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 621.10M |
| Total Debt | 37.99M |
| Net Cash | 583.12M |
| Net Cash Per Share | $6.84 |
| Equity (Book Value) | 487.28M |
| Book Value Per Share | 5.72 |
| Working Capital | 571.75M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -24.07M |
| Capital Expenditures | -8.01M |
| Depreciation & Amortization | 8.13M |
| Net Borrowing | n/a |
| Free Cash Flow | -32.08M |
| FCF Per Share | -$0.38 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -633.04% |
| Pretax Margin | -570.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -11.91% |
| Shareholder Yield | -11.91% |
| Earnings Yield | -16.42% |
| FCF Yield | -3.54% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $26.88 |
| Price Target Difference | 152.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | -4.78% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.09 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |